Since JAK/STAT pathway is involved in acquired resistance of HCC cells to sorafenib[180], these findings suggest that mutations in JAK1 may lead to failure of sorafenib treatment due to compensatory proliferation. This evidence concerns the gene SOAT1 and hepatocellular carcinoma.